Journal article
Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy
Leukemia & lymphoma, Vol.16(3-4), pp.199-207
1995
DOI: 10.3109/10428199509049758
PMID: 7719227
Abstract
Bispecific monoclonal antibodies (bsAbs) that recognize CD3 with one arm and a tumor associated antigen with the other arm can retarget T-cells toward tumor cells in an MHC independent manner, thereby combining the specificity of monoclonal antibodies with the power of the cellular immune system. B-cell malignancies are particularly attractive as targets for anti-CD3-based bsAb therapy because of their sensitivity to other forms of antibody therapy, and the extent to which B-cells and T-cells communicate at the molecular level. BsAbs that recognize CD3 and a number of antigens on malignant B-cells have been shown in vitro to be capable of retargeting T-cells. In animal models of B-cell malignancy, bsAb can eliminate tumor loads that are resistant to unmodified monoclonal antibody therapy. Ongoing early clinical trials in advanced B-cell lymphoma indicate CD3-based bsAbs have significant biologic effects, and suggest they have anti-tumor activity as well. A number of significant questions relating to bsAb therapy of B-cell malignancies remain. It is unclear what role both endogenously produced and exogenously administered cytokines are likely to play. Further exploration of whether bsAb can induce T-cells to target to tumor will also be required before the true promise of this novel form of immunotherapy can be determined.
Details
- Title: Subtitle
- Bispecific Monoclonal Antibody Therapy of B-Cell Malignancy
- Creators
- George J. Weiner - University of IowaGijsbert C. De Gast - Utrecht University
- Resource Type
- Journal article
- Publication Details
- Leukemia & lymphoma, Vol.16(3-4), pp.199-207
- Publisher
- Informa UK Ltd
- DOI
- 10.3109/10428199509049758
- PMID
- 7719227
- ISSN
- 1042-8194
- eISSN
- 1029-2403
- Language
- English
- Date published
- 1995
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Pharmaceutical Sciences and Experimental Therapeutics; Internal Medicine
- Record Identifier
- 9984360159502771
Metrics
15 Record Views